Following the acquisition, the joint ventures will be completely owned by Biogen and will be named as Biogen Idec Italia and Biogen Idec Switzerland.
The joint venture collaboration between the two firms started in 1997 as Biogen Dompe in Italy and Switzerland with initial focus on the commercialization of Avonex and then expanded to include commercial, distribution and service rights for Tysabri upon the therapy’s approval.
Dompe Group is an Italian biopharmaceutical company engaged in pharmaceutical process, from R&D to production and commercialization.